Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DXCM
STRONG BUYFLAGDexCom, Inc. · Healthcare · United States · $27.6B · Avg Vol: $348M/d
DexCom has strong quality at Q81 and momentum M73, but value at V32 is well below the calibrated floor, so stage one fails. Insider selling is separately adverse.
COMPANY DESCRIPTION
DexCom, Inc. develops, manufactures, and markets innovative continuous glucose monitoring (CGM) systems for people with diabetes. The company is a market leader in real-time CGM technology, offering advanced, highly accurate, and user-friendly devices that significantly improve diabetes management. DexCom is expanding market access and enhancing its technology to serve a growing global diabetic population.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9B | 3.6B | 4.0B | 4.7B | 17.0% | 4.8B | 5.2B | 5.8B | 11.8% |
| EPS | 0.88 | 1.40 | 1.46 | 2.14 | 34.5% | 2.30 | 2.65 | 3.15 | 21.3% |
| Shares | 386.3M | 385.4M | 390.7M | 384.8M | -0.4% | 385.9M | — | — | — |
| Debt | 2.1B | 2.6B | 2.6B | 1.4B | -13.5% | 1.4B | — | — | — |
| Equity | 2.1B | 2.1B | 2.1B | 2.7B | 8.8% | — | — | — | — |
| Op CF | 669.5M | 748.5M | 989.5M | 1.4B | 29.1% | 1.8B | — | — | — |
| Inv CF | -521.5M | -507.2M | -207.5M | 536.0M | — | — | — | — | — |
| Fin CF | -552.5M | -318.6M | -734.8M | -1.7B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DXCM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DXCM | DexCom, Inc.(you) | $27.6B | 83 | STRONG BUY |
| STE | STERIS plc | $20.9B | 81 | STRONG BUY |
| GEHC.MX | GE HealthCare Technologies Inc. | $27.5B | 67 | BUY |
| ZBH | Zimmer Biomet Holdings, Inc. | $17.7B | 91 | STRONG BUY |
| EW | Edwards Lifesciences Corporation | $47.6B | 72 | BUY |
| GMED | Globus Medical, Inc. | $10.4B | 93 | STRONG BUY |
| BIO-B | Bio-Rad Laboratories, Inc. | $8.3B | 72 | BUY |
| BSX.MX | Boston Scientific Corporation | $66.0B | 63 | HOLD |
| PEN | Penumbra, Inc. | $12.5B | 53 | HOLD |
| BRKR | Bruker Corporation | $9.2B | 59 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%